IDT.AX : Summary for IDT AUST FPO - Yahoo Finance

U.S. Markets closed
Loading...
Loading...
  • PR Newswire18 days ago

    IDT Announces Launch of Temozolomide Capsules In the US

    MELBOURNE, Australia, Nov. 22, 2016 /PRNewswire/ -- Mayne Pharma Group Limited (Mayne Pharma, ASX:MYX) has today announced the U.S. launch of IDT's generic temozolomide 5mg, 20mg, 100mg, 140mg, 180mg and ...

  • PR Newswirelast month

    PharmaVentures Advises IDT Australia on the Divestment of CMAX Clinical Trial Business to the Japanese Company I'rom Group Co. Ltd.

    The acquisition is subject to the satisfaction of certain conditions precedent, and as part of the agreed upon structure of the deal, IDT will establish and integrate the CMAX business within a new company (henceforth referred to as NewCo). This will allow I'rom Group to integrate the CMAX business and to learn from IDT's experience in managing CMAX, paving the way for I'rom Group to acquire the remaining shares of NewCo over the next twelve months.

  • PR Newswirelast month

    IDT Australia Divests CMAX Clinical Trial Business to I'rom Group Co. Ltd

    MELBOURNE, Australia, Oct. 28, 2016 /PRNewswire/ -- Australian pharmaceutical manufacturing and drug development company IDT Australia Limited (ASX:  IDT) announced that it has executed an agreement with Japanese integrated healthcare company I'rom Group Co. Ltd (see: http://www.iromgroup.co.jp/en/) for I'rom Group to acquire IDT's CMAX Clinical Trial Business. IDT will receive a minimum AU$14,000,000 in consideration for the CMAX business in a staged transaction as further described below. The acquisition is subject to the satisfaction of certain conditions precedent, and as part of the agreed upon structure of the deal, IDT will establish and integrate the CMAX business within a new company (henceforth referred to as  NewCo).